1
|
Itamochi H: Targeted therapies in
epithelial ovarian cancer: molecular mechanisms of action. World J
Biol Chem. 1:209–220. 2010. View Article : Google Scholar : PubMed/NCBI
|
2
|
Gibb EA, Brown CJ and Lam WL: The
functional role of long non-coding RNA in human carcinomas. Mol
Cancer. 10:382011. View Article : Google Scholar : PubMed/NCBI
|
3
|
Miyoshi N, Wagatsuma H, Wakana S, et al:
Identification of an imprinted gene, Meg3/Gtl2 and its human
homologue MEG3, first mapped on mouse distal chromosome 12
and human chromosome 14q. Genes Cell. 5:211–220. 2000.
|
4
|
Zhang X, Zhou Y, Mehta KR, et al: A
pituitary-derived MEG3 isoform functions as a growth suppressor in
tumor cells. J Clin Endocrinol Metab. 88:5119–5126. 2003.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Zhou Y, Zhang X and Klibanski A:
MEG3 noncoding RNA: a tumor suppressor. J Mol Endocrinol.
48:R45–R53. 2012. View Article : Google Scholar
|
6
|
Zhao J, Dahle D, Zhou Y, Zhang X and
Klibanski A: Hypermethylation of the promoter region is associated
with the loss of MEG3 gene expression in human pituitary
tumors. J Clin Endocrinol Metab. 90:2179–2186. 2005. View Article : Google Scholar : PubMed/NCBI
|
7
|
Zhang X, Gejman R, Mahta A, et al:
Maternally expressed gene 3, an imprinted noncoding RNA
gene, is associated with meningioma pathogenesis and progression.
Cancer Res. 70:2350–2358. 2010. View Article : Google Scholar
|
8
|
Astuti D, Latif F, Wagner K, et al:
Epigenetic alteration at the DLK1-GTL2 imprinted domain in
human neoplasia: analysis of neuroblastoma, phaeochromocytoma and
Wilms’ tumour. Br J Cancer. 92:1574–1580. 2005.PubMed/NCBI
|
9
|
Zhou Y, Zhong Y, Wang Y, et al: Activation
of p53 by MEG3 non-coding RNA. J Biol Chem. 282:24731–24742. 2007.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Braconi C, Kogure T, Valeri N, et al:
microRNA-29 can regulate expression of the long non-coding RNA gene
MEG3 in hepatocellular cancer. Oncogene. 30:4750–4756. 2011.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Wang P, Ren Z and Sun P: Overexpression of
the long non-coding RNA MEG3 impairs in vitro glioma cell
proliferation. J Cell Biochem. 113:1868–1874. 2012. View Article : Google Scholar : PubMed/NCBI
|
12
|
Benetatos L, Hatzimichael E, Dasoula A, et
al: CpG methylation analysis of the MEG3 and SNRPN imprinted genes
in acute myeloid leukemia and myelodysplastic syndromes. Leuk Res.
34:148–153. 2010. View Article : Google Scholar : PubMed/NCBI
|
13
|
Feng S, Cong S, Zhang X, et al:
MicroRNA-192 targeting retinoblastoma 1 inhibits cell proliferation
and induces cell apoptosis in lung cancer cells. Nucleic Acids Res.
39:6669–6678. 2011. View Article : Google Scholar : PubMed/NCBI
|
14
|
Anwar SL, Krech T, Hasemeier B, et al:
Loss of imprinting and allelic switching at the DLK1-MEG3
locus in human hepatocellular carcinoma. PLoS One. 7:e494622012.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Benetatos L, Vartholomatos G and
Hatzimichael E: MEG3 imprinted gene contribution in tumorigenesis.
Int J Cancer. 129:773–779. 2011. View Article : Google Scholar : PubMed/NCBI
|
16
|
Kagami M, O’Sullivan MJ, Green AJ, et al:
The IG-DMR and the MEG3-DMR at human chromosome 14q32.2:
hierarchical interaction and distinct functional properties as
imprinting control centers. PLoS Genet. 6:e10009922010.PubMed/NCBI
|
17
|
Jones PA and Baylin SB: The fundamental
role of epigenetic events in cancer. Nat Rev Genet. 3:415–428.
2002.PubMed/NCBI
|
18
|
Baylin SB and Ohm JE: Epigenetic gene
silencing in cancer - a mechanism for early oncogenic pathway
addiction? Nat Rev Cancer. 6:107–116. 2006. View Article : Google Scholar : PubMed/NCBI
|
19
|
Yoon JH, Dammann R and Pfeifer GP:
Hypermethylation of the CpG island of the RASSF1A gene in
ovarian and renal cell carcinomas. Int J Cancer. 94:212–217.
2001.PubMed/NCBI
|
20
|
Ibanez de Caceres I, Battagli C, Esteller
M, et al: Tumor cell-specific BRCA1 and RASSF1A
hypermethylation in serum, plasma, and peritoneal fluid from
ovarian cancer patients. Cancer Res. 64:6476–6481. 2004.
|
21
|
Chan KY, Ozçelik H, Cheung AN, Ngan HY and
Khoo US: Epigenetic factors controlling the BRCA1 and
BRCA2 genes in sporadic ovarian cancer. Cancer Res.
62:4151–4156. 2002.PubMed/NCBI
|
22
|
Kim T, Veronese A, Pichiorri F, et al: p53
regulates epithelial-mesenchymal transition through microRNAs
targeting ZEB1 and ZEB2. J Exp Med. 208:875–883. 2011. View Article : Google Scholar : PubMed/NCBI
|
23
|
Huarte M, Guttman M, Feldser D, et al: A
large intergenic noncoding RNA induced by p53 mediates global gene
repression in the p53 response. Cell. 142:409–419. 2010. View Article : Google Scholar : PubMed/NCBI
|
24
|
Brooks CL and Gu W: p53 regulation by
ubiquitin. FEBS Lett. 585:2803–2809. 2011. View Article : Google Scholar : PubMed/NCBI
|
25
|
Staub J, Chien J, Pan Y, et al: Epigenetic
silencing of HSulf-1 in ovarian cancer:implications in
chemoresistance. Oncogene. 26:4969–4978. 2007. View Article : Google Scholar : PubMed/NCBI
|